Prognostic significance of vascular endothelial growth factor expression in esophageal carcinoma: A meta-analysis

Journal of B.U.ON.

Volumn 18, Issue 2, 2013, Pages 398-406

  Peng, Jun ^a   Shao, Na ^a   Peng, Hongling ^a   Chen, Long Qi ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Esophageal carcinoma; Meta analysis; Prognostic factor; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ARTICLE; ASIAN; CANCER PATIENT; CANCER PROGNOSIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CARCINOMA; HISTOPATHOLOGY; HUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; SYSTEMATIC REVIEW;

ADENOCARCINOMA; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; HUMANS; ODDS RATIO; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84879583865     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Shimada H, Hoshino T, Okazumi S et al. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer 2002; 86: 552-557. (Pubitemid 34185091)
2. McCabe ML, Dlamini Z. The molecular mechanisms of oesophageal cancer. Int Immunopharmacol 2005; 5: 1113-1130. (Pubitemid 40725707)
3. Waraich N, Rashid F, Jan A et al. Vascular invasion is not a risk factor in oesophageal cancer recurrence. Int J Surg 2011; 9: 237-240.
4. Tanaka T, Ishiguro H, Kuwabara Y et al. Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Cancer Res 2010; 29: 83.
5. Koide N, Nishio A, Hiraguri M et al. Coexpression of vascular endothelial growth factor and p53 protein in squamous cell carcinoma of the esophagus. Am J Gastroenterol 2001; 96: 1733-1740. (Pubitemid 32552352)
6. Shimada Y, Imamura M, Watanabe G et al. Prognostic factors of oesophageal squamous cell carcinoma from the perspective of molecular biology. Br J Cancer 1999; 80: 1281-1288. (Pubitemid 29264093)
7. Couvelard A, Paraf F, Gratio V et al. Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J Pathol 2000; 192: 14-18.
8. Yilmaz A, Ernam D, Unsal E et al. Vascular endothelial growth factor immunostaining correlates with post--operative relapse and survival in non-small cell lung cancer. Arch Med Res 2007; 38: 764-768. (Pubitemid 47368722)
9. Harada Y, Ogata Y, Shirouzu K. Expression of vascular endothelial growth factor and its receptor KDR (kinase domain-containing receptor)/Flk-1 (fetal liver kinase-1) as prognostic factors in human colorectal cancer. Int J Clin Oncol 2001; 6: 221-228. (Pubitemid 33111358)
10. Weidner N, Carroll PR, Flax J et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-409. (Pubitemid 24058195)
11. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
12. Leung DW, Cachianes G, Kuang WJ et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309. (Pubitemid 20066716)
13. Bradbury PA, Zhai R, Ma C et al. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res 2009; 15: 4680-4685.
14. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 1: 795-803. (Pubitemid 37328914)
15. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027. (Pubitemid 46202320)
16. Kleespies A, Bruns CJ, Jauch KW. Clinical significance of VEGF-A, -C and -D expression in esophageal malignancies. Onkologie 2005; 28: 281-288. (Pubitemid 40754676)
17. Kozlowski M, Kowalczuk O, Milewski R et al. Serum vascular endothelial growth factors C and D in patients with oesophageal cancer. Eur J Cardiothorac Surg 2010; 38: 260-267.
18. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 2001; 323: 224-228.
19. Des Guetz G, Uzzan B, Nicolas P et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006; 94: 1823-1832. (Pubitemid 43882572)
20. Ahn MJ, Jang SJ, Park YW et al. Clinical prognostic values of vascular endothelial growth factor, microvessel density,and p53 expression in esophageal carcinomas. J Korean Med Sci 2002; 17: 201-207.
21. Choi JY, Jang KT, Shim YM et al. Prognostic significance of vascular endothelial growth factor expression and microvessel density in esophageal squamous cell carcinoma: comparison with positron emission tomography. Ann Surg Oncol 2006; 13: 1054-1062. (Pubitemid 44337964)
22. Inoue K, Ozeki Y, Suganuma T et al. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997; 79: 206-213. (Pubitemid 27029883)
23. Kitadai Y, Haruma K, Tokutomi T et al. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res 1998; 4: 2195-2200. (Pubitemid 28415667)
24. Ogata Y, Fujita H, Yamana H et al. Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: long-term follow-up study. World J Surg 2003; 27: 584-589. (Pubitemid 36961131)
25. Rosa AR, Schirmer CC, Gurski RR et al. Prognostic value of p53 protein expression and vascular endothelial growth factor expression in resected squamous cell carcinoma of the esophagus. Dis Esophagus 2003; 16: 112-118. (Pubitemid 36992384)
26. Uchida S, Shimada Y, Watanabe G et al. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 1998; 77: 1704-1709. (Pubitemid 28230478)
27. Cavazzola LT, Rosa AR, Schirmer CC et al. Immunohistochemical evaluation for P53 and VEGF (Vascular Endothelial Growth Factor) is not prognostic for long term survival in end stage esophageal adenocarcinoma. Rev Col Bras Cir 2009; 36: 24-34.
28. Kimura Y, Watanabe M, Ohga T et al. Vascular endothelial growth factor C expression correlates with lymphatic involvement and poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep 2003; 10: 1747-1751.
29. Kozlowski M, Naumnik W, Niklinski J et al. Vascular endothelial growth factor C and D expression correlates with lymph node metastasis and poor prognosis in patients with resected esophageal cancer. Neoplasma 2011; 58: 311-319.
30. Mobius C, Freire J, Becker I et al. VEGF-C expression in squamous cell carcinoma and adenocarcinoma of the esophagus. World J Surg 2007; 31: 1768-1772; discussion 1773-1764.
31. Liu P, Chen W, Zhu H et al. Expression of VEGF-C correlates with a poor prognosis based on analysis of prognostic factors in 73 patients with esophageal squamous cell carcinomas. Jpn J Clin Oncol 2009; 39: 644-650.
32. Tzao C, Lee SC, Tung HJ et al. Expression of hypoxia-inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF)-D as outcome predictors in resected esophageal squamous cell carcinoma. Dis Markers 2008; 25: 141-148.
33. Noguchi T, Takeno S, Shibata T et al. VEGF-C expression correlates with histological differentiation and metastasis in squamous cell carcinoma of the esophagus. Oncol Rep 2002; 9: 995-999.
34. Kato H, Yoshikawa M, Miyazaki T et al. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma. Anticancer Res 2002; 22: 3977-3984. (Pubitemid 36134422)
35. Li Z, Shimada Y, Uchida S et al. TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma. Int J Oncol 2000; 17: 453-460.
36. Okazawa T, Yoshida T, Shirai Y et al. Expression of vascular endothelial growth factor C is a prognostic indicator in esophageal cancer. Hepatogastroenterology 2008; 55: 1503-1508.
37. Nakagawa S, Nishimaki T, Kanda T et al. Clinical Significance of VEGF and dThdPase Expressions in Squamous Cell Carcinoma of the Esophagus. Acta Med Biol 2003; 51: 87-95. (Pubitemid 37493699)
38. Xu WG, Yang GL, Zhou LX et al. Prognostic value of VEGF expression in primary esophageal squamous cell carcinoma. Chin J Cancer Res 2004; 16: 85-89.
39. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
40. Chen J, Li T, Wu Y et al. Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2011; 137: 1799-1812.
41. Zhan P, Wang J, Lv XJ et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 2009; 4: 1094-1103.
42. Schoenleber SJ, Kurtz DM, Talwalkar JA et al. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009; 100: 1385-1392.
43. Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 2005; 11: 1434-1440. (Pubitemid 40315223)
44. Bang YJ, Kang YK, Kang WK et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 2011; 29: 1449-1458.
45. Shah MA, Jhawer M, Ilson DH et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011; 29: 868-874.
46. Shah MA, Ramanathan RK, Ilson DH et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24: 5201-5206. (Pubitemid 46631363)